A group of researchers, including oncologists and data scientists, from the University of Florida and Indiana University hypothesized that GLP-1s hold promise in oncology due to their ability to lower glucose, adiposity, insulin resistance, and systemic inflammation factors associated with cancer progression, according to a July 2025 paper published in JAMA
Notably, sKER-065, is an investigational new drug developed by Keros Therapeutics with a unique design
Whilst there is consensus appreciation of the reduction in perioperative cardiometabolic complications these agents provide in improving glycaemic control, it would be remiss to discount the unquantified risk of aspiration from GLP-1 agonists during airway management
8, 2025 FAYETTEVILLE, Ark
Drink water with your coffee to help your kidneys filter excess glucose from your blood
A cotton shirt